



# Central Nervous System Tumor Post-HSCT Data

## Registry Use Only

Sequence Number:

Date Received:

CIBMTR Center Number:

CIBMTR Recipient ID:

Today's Date:  /  /  20

Date of HSCT for which this form is being completed:  /  /

HSCT type:  autologous  allogeneic, unrelated  allogeneic, related  syngeneic (identical twin)

Product type:  marrow  PBSC  cord blood  multiple cord blood units infused  other product, specify: \_\_\_\_\_

Visit:  100 day  6 month  1 year  2 years  > 2 years, specify:

To be completed in conjunction with a Form 2100 – 100 Days Post-HSCT Data, Form 2200 – Six Months to Two Years Post-HSCT Data, or Form 2300 – Yearly Follow-Up for Greater Than Two Years Post-HSCT Data. Information reported here should reflect the date of last contact as reported in the post-HSCT data collection form, or immediately prior to death.

## Disease Assessment at the Time of Best Response to HSCT

Best response is based on response to the HSCT, but does NOT include response to any therapy given for disease relapse or progression post-HSCT. When determining the best response to HSCT, compare the post-HSCT disease status to the status immediately prior to the preparative regimen, regardless of time since HSCT. This comparison is meant to capture the BEST disease status in response to HSCT that occurred in the reporting interval, even if a subsequent disease relapse or progression occurred during the same reporting interval. If a recipient already achieved their best response in a previous reporting interval, confirm the best response and check the box to indicate "date previously reported."

1. Compared to the disease status prior to the preparative regimen, what was the best response to HSCT since the date of the last report? (Include response to any planned post-HSCT surgical resection or irradiation.)

- 1  continued complete response (CCR) — continued absence of all disease after a complete response from the pre-HSCT disease status
- 2  complete response (CR) — complete disappearance of all sites of known disease for > 4 weeks
- 3  complete response undetermined (CRU) — complete response with persistence of radiographic enhancing abnormalities of unknown significance
- 4  partial response (PR) — ≥ 50% reduction in greatest diameter of all sites of known disease, and no new sites of disease for > 4 weeks
- 5  no response (NR) — < 50% reduction in greatest diameter of any known sites of disease, and no new sites of disease for > 4 weeks
- 6  progressive disease (PD) — increase in size of any site of known disease, or any new sites of disease
- 7  not assessed

2. Date best response first began:  /  /   date for the best response was previously reported

## Relapse or Progression Post-HSCT

3. Has the disease relapsed or progressed since the date of the last report?

- 1  yes →
- 2  no
- 3  unknown

4. Date of progression / relapse:  /  /  20  date unknown

**Mail this form to your designated campus (Milwaukee or Minneapolis). Retain the original at the transplant center.**

CIBMTR Center Number:

CIBMTR Recipient ID:

5. *Allogeneic HSCTs only*: Was there subsequent disease stability or regression without further therapy (so-called graft-versus-tumor effect)?

- 1  yes
- 2  no
- 3  unknown

6. Did this change in disease status qualify as a partial response or better if compared to a post-HSCT imaging study? (see page 1 for criteria to define partial response)

- 1  yes
- 2  no

7. Date of response:

Month Day Year

date unknown

Specify site(s) of tumor recurrence / progression:

- 8. 1  yes 2  no 3  unknown Cerebrospinal fluid
- 9. 1  yes 2  no 3  unknown Extraneural
- 10. 1  yes 2  no 3  unknown Distant intracranial parenchymal
- 11. 1  yes 2  no 3  unknown Intracranial leptomeningeal
- 12. 1  yes 2  no 3  unknown Spinal leptomeningeal
- 13. 1  yes 2  no 3  unknown Local primary site
- 14. 1  yes 2  no 3  unknown Other site

15. Specify site:

### Post-HSCT Planned Treatment for CNS Disease

16. Was planned treatment given per protocol since the date of the last report? (Include any maintenance therapy, but exclude any treatment for persistent, progressive or recurrent disease.)

- 1  yes
- 2  no

**Radiation Therapy:** 17. 1  yes 2  no → cont. with q. 38

Date radiation therapy started: 18.

Date radiation therapy stopped: 19.

Specify radiation field(s):

Whole brain 20. 1  yes 2  no 21. If yes, specify total dose:     cGy (rads)

Local cranial 22. 1  yes 2  no 23. If yes, specify total dose:     cGy (rads)

Craniospinal 24. 1  yes 2  no 25. If yes, specify total dose:     cGy (rads)

Gamma knife / radiosurgery 26. 1  yes 2  no 27. If yes, specify total dose:     cGy (rads)

Interstitial irradiation / brachytherapy 28. 1  yes 2  no 29. If yes, specify total dose:     cGy (rads)

Radioactive instillation 30. 1  yes 2  no 31. If yes, specify total dose:     cGy (rads)

Local spinal 32. 1  yes 2  no 33. If yes, specify total dose:     cGy (rads)

Other radiation field 34. 1  yes 2  no 35. If yes, specify total dose:     cGy (rads)

Specify other radiation field 36.

Specify fractionation schedule: 37. 1  single 2  single daily 3  multiple daily 4  other schedule

**Surgical Biopsy / Resection:** 38. 1  yes 2  no → cont. with q. 44

Date of surgery: 39.

Type of surgery: 40.

#### Codes for Type of Surgery

- 1 Gross total resection – > 95% resection, no radiographic residual tumor
- 2 Near total resection – 90-95% resection, minimal radiographic residual tumor
- 3 Subtotal resection – 51-89% resection, moderate radiographic residual tumor
- 4 Partial resection – 10-50% resection, significant radiographic residual tumor
- 5 Biopsy only – < 10% resection, no radiographic change post-op from pre-op

CIBMTR Center Number:

CIBMTR Recipient ID:

- Codes for Size of Residual Tumor after Surgery**
- 1 None (no radiographic residual tumor)
  - 2 Less than 1.5 cm, with radiographic residual tumor
  - 3 1.5 to less than 3.0 cm
  - 4 3.0 to 6.0 cm
  - 5 > 6.0 cm
  - 6 Not evaluable
  - 7 Unknown

Size of residual tumor after surgery (see codes at left) 41.

Was the extent of the surgical resection confirmed radiographically? 42. 1  yes 2  no 3  unknown

Was any persistent, viable tumor detected? 43. 1  yes 2  no 3  unknown

**Best Response to Line of Therapy:** (see definitions at question 1)

44. 1  CCR 2  CR 3  CRU 4  PR  
5  NR 6  PD 7  not assessed →

45. If code 7, specify reason:  
1  toxic death before disease evaluation  
2  other reason

Date the best response, including planned post-HSCT treatment, was achieved: 46.        
Month Day Year

Copy this page to report more than one line of therapy; check here  if additional pages are attached.

### Post-HSCT Treatment for Persistent, Progressive, or Recurrent CNS Disease

47. Was treatment given for persistent, progressive or recurrent CNS disease since the date of the last report?

- 1  yes →
- 2  no

**Systemic therapy:** 48. 1  yes 2  no → cont. with q. 71

Date therapy started: 49.      
Month Day Year

Date therapy stopped: 50.      
Month Day Year

Number of cycles: 51.    unknown / not applicable

bleomycin (BLM, Blenoxane) 52. 1  yes 2  no

carboplatin (Paraplatin) 53. 1  yes 2  no

cisplatin (Platinol, CDDP) 54. 1  yes 2  no

corticosteroids 55. 1  yes 2  no

cyclophosphamide (Cytoxan) 56. 1  yes 2  no

etoposide (VP-16, VePesid) 57. 1  yes 2  no

ifosfamide (Ifex) 58. 1  yes 2  no

melphalan (L-PAM, Alkeran) 59. 1  yes 2  no

methotrexate (MTX, Folex) 60. 1  yes 2  no

nitrosourea (carmustine) 61. 1  yes 2  no

procarbazine (Matulane) 62. 1  yes 2  no

temozolomide (Temodar) 63. 1  yes 2  no

thiotepa (Thioplex) 64. 1  yes 2  no

topotecan (Hycamtin) 65. 1  yes 2  no

vincristine (VCR, Oncovin) 66. 1  yes 2  no

other therapy 67. 1  yes 2  no

specify other therapy 68. \_\_\_\_\_

Hematopoietic growth factor? 69. 1  yes 2  no

# of chemo cycles used with: 70. 1  < 5 2  ≥ 5 3  unknown

**Radiation Therapy:** 71. 1  yes 2  no → cont. with q. 92

Date radiation therapy started: 72.      
Month Day Year

Date radiation therapy stopped: 73.      
Month Day Year

Specify radiation field(s):

Whole brain 74. 1  yes 2  no 75. If yes, specify total dose:     cGy (rads)

Local cranial 76. 1  yes 2  no 77. If yes, specify total dose:     cGy (rads)

Craniospinal 78. 1  yes 2  no 79. If yes, specify total dose:     cGy (rads)

CIBMTR Center Number:

CIBMTR Recipient ID:

- Codes for Type of Surgery**
- 1 Gross total resection – > 95% resection, no radiographic residual tumor
  - 2 Near total resection – 90-95% resection, minimal radiographic residual tumor
  - 3 Subtotal resection – 51-89% resection, moderate radiographic residual tumor
  - 4 Partial resection – 10-50% resection, significant radiographic residual tumor
  - 5 Biopsy only – < 10% resection, no radiographic change post-op from pre-op

- Codes for Size of Residual Tumor after Surgery**
- 1 None (no radiographic residual tumor)
  - 2 Less than 1.5 cm, with radiographic residual tumor
  - 3 1.5 to less than 3.0 cm
  - 4 3.0 to 6.0 cm
  - 5 > 6.0 cm
  - 6 Not evaluable
  - 7 Unknown

Gamma knife / radiosurgery 80. 1  yes 2  no 81. If yes, specify total dose:  cGy (rads)

Interstitial irradiation / brachytherapy 82. 1  yes 2  no 83. If yes, specify total dose:  cGy (rads)

Radioactive instillation 84. 1  yes 2  no 85. If yes, specify total dose:  cGy (rads)

Local spinal 86. 1  yes 2  no 87. If yes, specify total dose:  cGy (rads)

Other radiation field 88. 1  yes 2  no 89. If yes, specify total dose:  cGy (rads)

Specify other radiation field 90. \_\_\_\_\_

Specify fractionation schedule: 91. 1  single 2  single daily 3  multiple daily 4  other schedule

**Surgical Biopsy / Resection:** 92. 1  yes 2  no → cont. with q. 98

Date of surgery: 93.        
Month Day Year

Type of surgery: 94.   
(see codes at left)

Size of residual tumor after surgery (see codes at left) 95.

Was the extent of the surgical resection confirmed radiographically? 96. 1  yes 2  no 3  unknown

Was any persistent, viable tumor detected? 97. 1  yes 2  no 3  unknown

**Best Response to Line of Therapy:** 98. 1  CCR 2  CR 3  CRU 4  PR  
(see definitions at question 1) 5  NR 6  PD 7  not assessed →

Date the best response to post-HSCT treatment was achieved: 100.        
Month Day Year

99. If code 7, specify reason:  
 1  toxic death before disease evaluation  
 2  other reason

**Copy this page to report more than one line of therapy; check here  if additional pages are attached.**

### Disease Status at the Time of Assessment for This Reporting Period

101. What is the current disease status?

- 1  complete remission
- 2  not in complete remission

102. Date the current disease status was established in this reporting period:        
Month Day Year

103. Signed: \_\_\_\_\_  
Person completing form

Please print name: \_\_\_\_\_

Phone: (\_\_\_\_\_) \_\_\_\_\_

Fax: (\_\_\_\_\_) \_\_\_\_\_

E-mail address: \_\_\_\_\_